TrialGynecologic oncology2017

A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.

David M Hyman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.